BRPI0411364A - compostos tendo atividade inibidora de fosfatidilinositol 3-cinase e métodos de uso dos mesmos - Google Patents

compostos tendo atividade inibidora de fosfatidilinositol 3-cinase e métodos de uso dos mesmos

Info

Publication number
BRPI0411364A
BRPI0411364A BRPI0411364-0A BRPI0411364A BRPI0411364A BR PI0411364 A BRPI0411364 A BR PI0411364A BR PI0411364 A BRPI0411364 A BR PI0411364A BR PI0411364 A BRPI0411364 A BR PI0411364A
Authority
BR
Brazil
Prior art keywords
compounds
methods
phosphatidylinositol
inhibitory activity
kinase inhibitory
Prior art date
Application number
BRPI0411364-0A
Other languages
English (en)
Inventor
Beth E Drees
Leena Chakravarty
Glenn D Prestwich
Gyorgy Dorman
Mariann Kavecz
Andras Lukacs
Laszlo Urge
Ferenc Darvas
Piotr W Rzepecki
Collin G Ferguson
Original Assignee
Zentaris Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zentaris Gmbh filed Critical Zentaris Gmbh
Publication of BRPI0411364A publication Critical patent/BRPI0411364A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/48—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving transferase
    • C12Q1/485—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving transferase involving kinase
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/02—Screening involving studying the effect of compounds C on the interaction between interacting molecules A and B (e.g. A = enzyme and B = substrate for A, or A = receptor and B = ligand for the receptor)

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Urology & Nephrology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Genetics & Genomics (AREA)
  • Rheumatology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Oncology (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Pain & Pain Management (AREA)
  • Ophthalmology & Optometry (AREA)
  • Dermatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)

Abstract

"COMPOSTOS TENDO ATIVIDADE INIBIDORA DE FOSFATIDILINOSITOL 3-CINASE E MéTODOS DE USO DOS MESMOS". A presente invenção refere-se a compostos inibindo as atividades de fosfatidilinositol 3-cinase (PI 3-K) e métodos de preparação e uso dos mesmos no tratamento de doenças são descritos. Os compostos que inibem a atividade da PI 3-K e métodos de uso de compostos inibidores de PI 3-K para inibir o crescimento de célula cancerosa ou para tratar distúrbios de imunidade e inflamação, onde PI 3-K desempenha um papel no funcionamento de leucócito são também providos.
BRPI0411364-0A 2003-06-13 2004-06-14 compostos tendo atividade inibidora de fosfatidilinositol 3-cinase e métodos de uso dos mesmos BRPI0411364A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US47822103P 2003-06-13 2003-06-13
PCT/US2004/018752 WO2005016245A2 (en) 2003-06-13 2004-06-14 Compounds having inhibitive activity of phosphatidylinositol 3-kinase and methods of use thereof

Publications (1)

Publication Number Publication Date
BRPI0411364A true BRPI0411364A (pt) 2006-07-25

Family

ID=34193025

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0411364-0A BRPI0411364A (pt) 2003-06-13 2004-06-14 compostos tendo atividade inibidora de fosfatidilinositol 3-cinase e métodos de uso dos mesmos

Country Status (13)

Country Link
US (1) US20070010548A1 (pt)
EP (1) EP1648463A2 (pt)
JP (1) JP2007500249A (pt)
KR (1) KR20060070486A (pt)
CN (1) CN1823067A (pt)
AU (1) AU2004264834A1 (pt)
BR (1) BRPI0411364A (pt)
CA (1) CA2528938A1 (pt)
IL (1) IL172426A0 (pt)
NO (1) NO20060210L (pt)
RU (1) RU2006100484A (pt)
WO (1) WO2005016245A2 (pt)
ZA (1) ZA200509961B (pt)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE455115T1 (de) * 2005-07-20 2010-01-15 Aventis Pharma Sa 1,4-dihydropyridine-kondensierte heterocyclen verfahren zu deren herstellung sowie verwendung und zusammensetzungen dergleichen
US20070238746A1 (en) 2006-04-06 2007-10-11 Trixi Brandl Thiazolyl-dihydro-chinazoline
US7691868B2 (en) 2006-04-06 2010-04-06 Boehringer Ingelheim International Gmbh Thiazolyl-dihydro-quinazoline
US7517995B2 (en) 2006-04-06 2009-04-14 Boehringer Ingelheim International Gmbh Thiazolyl-dihydro-cyclopentapyrazole
MY151089A (en) 2007-03-26 2014-04-15 Univ Southern California Usc Stevens Methods and compositions for inducing apoptosis by stimulating er stress
JP5502077B2 (ja) * 2008-06-05 2014-05-28 グラクソ グループ リミテッド 新規な化合物
WO2009147187A1 (en) * 2008-06-05 2009-12-10 Glaxo Group Limited 4-carboxamide indazole derivatives useful as inhibitors of p13-kinases
US8658635B2 (en) 2008-06-05 2014-02-25 Glaxosmithkline Intellectual Property Development Limited Benzpyrazol derivatives as inhibitors of PI3 kinases
EP2280705B1 (en) 2008-06-05 2014-10-08 Glaxo Group Limited Novel compounds
AR072845A1 (es) * 2008-07-29 2010-09-22 Boehringer Ingelheim Int 5-alquil-pirimidinas y su uso en el tratamiento de enfermedades mediadas por la actividad de quinasas.
WO2010102958A1 (en) 2009-03-09 2010-09-16 Glaxo Group Limited 4-oxadiazol-2 -yl- indazoles as inhibitors of p13 kinases
TWI466884B (zh) 2009-04-30 2015-01-01 Glaxo Group Ltd 6-(1h-吲哚-4-基)-4-(5-{[4-(1-甲基乙基)-1-哌嗪基]甲基}-1,3-噁唑-2-基)-1h-吲唑、其醫藥組合物及作為激酶活性抑制劑之用途
FR2945535B1 (fr) 2009-05-18 2011-06-10 Sanofi Aventis Compose anticancereux et composition pharmaceutique le contenant
EP2507226A1 (en) * 2009-12-03 2012-10-10 Glaxo Group Limited Novel compounds
JP2013512879A (ja) * 2009-12-03 2013-04-18 グラクソ グループ リミテッド Ｐｉ３キナーゼの阻害剤としてのベンズピラゾール誘導体
GB201018124D0 (en) 2010-10-27 2010-12-08 Glaxo Group Ltd Polymorphs and salts
HUE043853T2 (hu) * 2012-10-12 2019-09-30 Broad Inst Inc GSK3 inhibitorok és eljárások azok alkalmazására
EP3661924A1 (en) 2017-07-31 2020-06-10 The Trustees of Columbia University in the City of New York Compounds, compositionals, and methods for treating t-cell acute lymphoblastic leukemia
JP7508584B2 (ja) 2020-04-29 2024-07-01 リレー セラピューティクス， インコーポレイテッド ＰＩ３Ｋα阻害剤およびそれらの使用
JP2025519029A (ja) * 2022-05-10 2025-06-24 リレー セラピューティクス， インコーポレイテッド ＰＩ３Ｋα阻害剤及びその使用方法
CN115353515B (zh) * 2022-09-08 2025-06-13 上海润诺生物科技有限公司 一种医药中间体吡唑并喹啉酮衍生物的制备方法及催化剂

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3935222A (en) * 1975-04-16 1976-01-27 E. R. Squibb & Sons, Inc. 1,4,5,7-Tetrahydropyrazolo[3,4-b]pyridin-6-ones
GR79111B (pt) * 1982-12-20 1984-10-02 Lepetit Spa

Also Published As

Publication number Publication date
NO20060210L (no) 2006-03-01
IL172426A0 (en) 2006-04-10
CA2528938A1 (en) 2005-02-24
US20070010548A1 (en) 2007-01-11
EP1648463A2 (en) 2006-04-26
CN1823067A (zh) 2006-08-23
KR20060070486A (ko) 2006-06-23
WO2005016245A3 (en) 2005-06-02
ZA200509961B (en) 2006-10-25
JP2007500249A (ja) 2007-01-11
WO2005016245A2 (en) 2005-02-24
AU2004264834A1 (en) 2005-02-24
RU2006100484A (ru) 2006-06-10

Similar Documents

Publication Publication Date Title
BRPI0411364A (pt) compostos tendo atividade inibidora de fosfatidilinositol 3-cinase e métodos de uso dos mesmos
DK1438052T3 (da) Quinazolin-4-oner af inhibitorer som human phosphatidylinositol 3-kinase delta
DK1278748T3 (da) Inhibitorer af human phosphatidyl-inositol 3-kinase delta
BRPI0312464B8 (pt) compostos inibidores de tirosina quinases, composições farmacêuticas compreendendo os mesmos, processos para fabricação e usos dos mesmos
BR0208373A (pt) Inibidores da tirosina cinase
AU3804500A (en) 2-amino-6-anilino-purines and their use as medicaments
BRPI0415395A (pt) composto, métodos para inibir a atividade da proteìna quinase e para tratar um paciente que tenha uma condição que seja mediada pela atividade da proteìna quinase, e, composição
BR0314603A (pt) Uso de inibidores da sìntese de citoquina para o tratamento de distúrbios de olhos secos
EP2612862A3 (en) Quinazolinones as inhibitors of human phosphatidylinositol 3-kinase delta
ATE237324T1 (de) Dexanabinol-derivate und ihre verwendung als neuroprotektive pharmazeutische zusammensetzungen
BR0312957A (pt) Composto ou um sal farmaceuticamente aceitável deste, uso do mesmo, composição farmacêutica, e, método para produzir um efeito inibidor de 11betahsd1 em um animal de sangue quente, tal como o homem, em necessidade de tal tratamento
MEP36908A (en) omega-CARBOXYARYL SUBSTITUTED DIPHENYL UREAS AS RAF KINASE INHIBITORS
ATE415962T1 (de) Verwendung von asiatsäure oder asiaticosid zur behandlung von krebs
BRPI0513513A (pt) composto ou um sal farmaceuticamente aceitável do mesmo, processo para preparar o mesmo, composição farmacêutica, uso de um composto ou um sal farmaceuticamente aceitável do mesmo, e, métodos para produzir um efeito inibitório de eg5 e um efeito anticáncer em um animal de sangue quente, e para tratar carcinomas em um animal de sangue quente
BR0200921A (pt) Uso de produtos de legume para o tratamento de agressões externas
BR0213037A (pt) Derivados de pirimidina
ATE350032T1 (de) Verwendung der protein-kinase-c-epsilon- inhibitoren zur behandlung von schmerzen
BR0111897A (pt) Composto, método para tratar um indivìduo afligido por alguns distúrbios dos sistemas nervosos periférico e central, composição farmacêutica, e, uso de um composto
BRPI0408778A (pt) proteìnas ativadoras de elemento de resposta à amp cìclica e uso relacionado as mesmas
EP1939203A3 (en) Inhibitors of human phosphatidyl-inositol 3-kinase delta isoform
WO2005002514A3 (en) Compounds having inhibitibe activity of phosphatidylinositol 3-kinase and methods of use thereof
ATE311901T1 (de) Verwendung von tgf-beta inhibitoren zur behandlung von cerebralen krankheiten
BR0303384A (pt) Citalopram e seus usos no tratamento de pressão sanguìnea elevada

Legal Events

Date Code Title Description
B25G Requested change of headquarter approved

Owner name: ZENTARIS GMBH (DE)

Free format text: SEDE ALTERADA CONFORME PETICAO NO 020060058923-RJ DE 27.04.2006.

B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE AS 6A, 7A E 8A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2159 DE 22/05/2012.